Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide
NCT03186625 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2017-12-07
Summary
Recent studies highlight the participation of gut microbes in the pathogenesis of both atherosclerotic heart disease and its adverse thrombotic events. Trimethylamine N-oxide (TMAO) is a plasma metabolite shown to be formed through a metaorganismal pathway involving nutrient precursors abundant in a Western diet and the sequential action of gut microbiota. Numerous studies reveal an association between systemic TMAO levels and cardiovascular risks in a variety of stable cohorts. The purpose of this study is to evaluate the efficacy of traditional Chinese Medicine formular (Compound pseudo-ginseng granules ) on the level of TMAO for the patient with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention. 80 patients with ACS would be randomly allocated into interventional group(IG) and control group(CG). The patients in the IG would be administered by oral Compound pseudo-ginseng granules (twice per day ) for 90 days and those in the CG would receive the placebo twice per day during the same period. All of subjects would be administered with standard therapy in accordance with AHA/ACC guideline for ST-elevation myocardial infarction(STEMI) and Non ST-elevation myocardial infarction(NSTEMI).The primary endpoint is the plasma level of TMAO at 90-day follow-up. The second endpoint is the level of lipid, score of The Seattle Angina, fecal DNA extraction and pyrosequencing.
Conditions
- Acute Coronary Syndrome
Interventions
- DRUG
-
Compound Panax Notoginseng Granule
Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc. Frequency:two times a day, one package per time. Duration:three months.
- DRUG
-
Placebo Granule
Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Sponsors & Collaborators
-
Beijing Genomics Institute
collaborator OTHER -
Guangdong Provincial Hospital of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Xiaoyan Li, Master · Guangdong Provincial Hospital of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-05
- Primary Completion
- 2018-05-31
- Completion
- 2018-08-31
Countries
- China
Study Locations
More Related Trials
-
Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease
NCT00965471 ·Status: COMPLETED ·Phase: NA
-
Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
NCT01612260 ·Status: UNKNOWN ·Phase: PHASE4
-
Traditional Chinese Medicine for Treatment of Chronic Heart Failure
NCT01939236 ·Status: COMPLETED ·Phase: PHASE2
-
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
NCT03142529 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.
NCT03171597 ·Status: UNKNOWN ·Phase: PHASE4
-
Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index
NCT01502943 ·Status: COMPLETED ·Phase: PHASE4
-
Traditional Chinese Medicine for Severe COVID-19
NCT04323332 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Traditional Chinese Medicine of Severe COVID-19
NCT06714032 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine
NCT04022031 ·Status: UNKNOWN
-
Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)
NCT00817024 ·Status: COMPLETED ·Phase: NA
-
Study on the Therapeutic Effect of TCM Treatment for MDR MN
NCT02610595 ·Status: UNKNOWN ·Phase: NA
-
Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality
NCT03018769 ·Status: UNKNOWN
-
Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine
NCT05482009 ·Status: COMPLETED
-
Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris
NCT04661709 ·Status: UNKNOWN ·Phase: PHASE4
-
The Dampness Syndrome of Chinese Medicine Cohort Study
NCT05315895 ·Status: RECRUITING
-
Effect of Traditional Chinese Medicine on GI Function Recovery and Nutrition Support in SAP
NCT00508729 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina.
NCT03179527 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Study On The Relation Among Prescription, Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease
NCT02526381 ·Status: UNKNOWN ·Phase: NA
-
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection
NCT04251871 ·Status: UNKNOWN ·Phase: NA
-
Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia
NCT03185923 ·Status: UNKNOWN ·Phase: PHASE3
-
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
NCT07041359 ·Status: RECRUITING ·Phase: PHASE4
-
Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine
NCT04026724 ·Status: UNKNOWN
-
Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine
NCT05072990 ·Status: COMPLETED
-
Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine
NCT06613659 ·Status: NOT_YET_RECRUITING
-
Safety Study of Shenmai(a Chinese Medicine Injection) Used in Hospitals in China
NCT01612611 ·Status: UNKNOWN